Dongin (Donoven) Kim, Ph.D.

---

Publications & Presentations

41. Kim I, Kim T H, Ma K, Lee E S, Kim D, Oh K T, Lee D H, Lee K C, Youn Y S. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjugate chemistry. 2010; 21 : 1513-9

42. Dasari M, Lee S, Sy J, Kim D, Lee S, Brown M, Davis M, Murthy N. Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA. Organic letters. 2010; 12 : 3300-3

43. Kim D, Gao Z G, Lee E S, Bae Y H. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Molecular pharmaceutics. 2009; 6 : 1353-62

44. Oh K T, Kim D, You H H, Ahn Y S, Lee E S. pH-sensitive properties of surface charge-switched multifunctional polymeric micelle. International journal of pharmaceutics. 2009; 376 : 134-40

45. Kim D, Lee E S, Oh K T, Gao Z G, Bae Y H. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small (Weinheim an der Bergstrasse, Germany). 2008; 4 : 2043-50

Grants

1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.

2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.

3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.

5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

Awards and Honors

no results

Education

1. Degree: Ph D. University of Utah. Date: 2009.


2. Degree: MS. University of Florida. Date: 2002.


3. Degree: BS. Ajou University. Date: 1999.

Administrative Assignments

no results